UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.1718-1732

2021

Volltextzugriff (PDF)

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1580-1590

2020

Volltextzugriff (PDF)

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

European journal of cancer (1990), 2018-09, Vol.101, p.236-243

2018

Volltextzugriff (PDF)

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Critical care (London, England), 2021-08, Vol.25 (1), p.290-290, Article 290

2021

Volltextzugriff (PDF)

Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

Critical care (London, England), 2022-12, Vol.26 (1), p.373-373, Article 373

2022

Volltextzugriff (PDF)

Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial

Journal of antimicrobial chemotherapy, 2022-08, Vol.77 (9), p.2522-2531

2022

Volltextzugriff (PDF)

Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

Critical care (London, England), 2021-10, Vol.25 (1), p.354-354, Article 354

2021

Volltextzugriff (PDF)

Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia

Journal of antimicrobial chemotherapy, 2022-03, Vol.77 (4), p.1166-1177

2022

Volltextzugriff (PDF)

Ertapenem versus Cefotetan Prophylaxis in Elective Colorectal Surgery

The New England journal of medicine, 2006-12, Vol.355 (25), p.2640-2651

2006

Volltextzugriff (PDF)

Peer-Review Writing Workshops in College Courses: Students’ Perspectives about Online and Classroom Based Workshops

Social sciences (Basel), 2016-12, Vol.5 (4), p.72

Jensen, Erin

2016

Volltextzugriff (PDF)

Rotational Components of Normal Modes Measured at a Natural Sandstone Tower (Kane Springs Canyon, Utah, U.S.A.)

The Seismic record, 2022-10, Vol.2 (4), p.260-268

2022

Volltextzugriff (PDF)

Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

Annals of intensive care, 2023-02, Vol.13 (1), p.8-8, Article 8

2023

Volltextzugriff (PDF)

Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials

Open forum infectious diseases, 2020-07, Vol.7 (7), p.ofaa248-ofaa248

2020

Volltextzugriff (PDF)

Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis

Open forum infectious diseases, 2023-06, Vol.10 (6), p.ofad225-ofad225

2023

Volltextzugriff (PDF)

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)

Microbiology spectrum, 2024-03, Vol.12 (3), p.e0356323-e0356323

2024

Volltextzugriff (PDF)

Combined ambient vibration and surface displacement measurements for improved progressive failure monitoring at a toppling rock slab in Utah, USA

Frontiers in earth science (Lausanne), 2024-03, Vol.12

2024

Volltextzugriff (PDF)

Instructional Note: Creating Digital Research Posters in First-Year Writing Classes

Teaching English in the two-year college, 2024-03, Vol.51 (3), p.241-253

Jensen, Erin B.

2024

Volltextzugriff (PDF)

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50

Journal of clinical oncology, 2021-07, Vol.39 (21), p.2339-2349

2021

Volltextzugriff (PDF)

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Journal of clinical oncology, 2019-10, Vol.37 (28), p.2518-2527

2019

Volltextzugriff (PDF)

Polyethylene glycol versus sodium phosphate mechanical bowel preparation in elective colorectal surgery

The American journal of surgery, 2007-02, Vol.193 (2), p.190-194

2007

Volltextzugriff (PDF)

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1999-2006

2023

Volltextzugriff (PDF)

Attainment of ACC/AHA Recommended LDL-C Lowering With Statin and Ezetimibe+Statin Therapies

Journal of clinical lipidology, 2016-05, Vol.10 (3), p.683-684

2016

Volltextzugriff (PDF)

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1992-1998

2023

Volltextzugriff (PDF)

Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery

Surgical infections, 2008-04, Vol.9 (2), p.131-137

2008

Volltextzugriff (PDF)

Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults

Surgical infections, 2007-02, Vol.8 (1), p.15-28

2007

Volltextzugriff (PDF)

1 – 25 von 440

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(395)
Mit Volltextzugriff
(368)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial

Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia

Ertapenem versus Cefotetan Prophylaxis in Elective Colorectal Surgery

Peer-Review Writing Workshops in College Courses: Students’ Perspectives about Online and Classroom Based Workshops

Rotational Components of Normal Modes Measured at a Natural Sandstone Tower (Kane Springs Canyon, Utah, U.S.A.)

Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials

Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)

Combined ambient vibration and surface displacement measurements for improved progressive failure monitoring at a toppling rock slab in Utah, USA

Instructional Note: Creating Digital Research Posters in First-Year Writing Classes

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Polyethylene glycol versus sodium phosphate mechanical bowel preparation in elective colorectal surgery

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Attainment of ACC/AHA Recommended LDL-C Lowering With Statin and Ezetimibe+Statin Therapies

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery

Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults

Suchergebnisse filtern